摘要
Objective This work summarizes the clinical features and treatment of 10 AIDS patients with malignant lymphoma. Methods A total of 10 AIDS patients with malignant lymphoma seen in Beijing Ditan Hospital since 2009 were enrolled. Clinical manifestations, pathological examinations, immunity levels, Epstein-Barr virus antibody examinations, complications, treatments, and outcomes were retrospectively analyzed. Results The main clinical manifestations of these patients included intermittent fever in 2 cases, neck masses and fever in 3 cases, auxiliary lymph node enlargement in 2 cases, and abdominal pain and bloating with fever in 3 cases. Up to 7 patients were pathologically diagnosed with diffuse large B cell lymphoma （DLBCL）, and 3 patients were pathologically diagnosed with Burkitt＇s lymphoma. Up to 8 patients had CD4 cell counts below 200/μL, and 2 patients had a level of more than 200/μL. Up to 7 patients were negative for EBV-IgM antibodies and 3 patients were not examined. Six patients underwent different chemotherapy and their prognoses were different. One patient with Burkitt＇s lymphoma alternatively took CODOXM and IVAC for 3 turns after VP chemotherapy; 1 patient with liver metastasis took R-CHOP 5 times, then changed therapy regimen to R-MINE and MINE. One patient with adrenal DLBCL took CHOP 6 times. Three patients with DLBCL took CHOP 1 or 2 times. Four patients gave up treatment. Various infections and side effects occurred, including bone marrow suppression, gastrointestinal bleeding, and renal dysfunction during chemotherapy. Six patients took HAARI, and 4 did not. Six patients died, whereas 3 patients got improved; and 1 patient was discharged. Conclusions AIDS patients with malignant lymphoma had various clinical manifestations, were immunocompromised, and had multiple metastases when they were admitted; they were already in the interim or late stage of lymphoma. Chemotherapy was not effective, and additional complications occurred. HAART failed to improve patient prognosis, and the overall prognosis was poor.
Objective This work summarizes the clinical features and treatment of 10 AIDS patients with malignant lymphoma. Methods A total of 10 AIDS patients with malignant lymphoma seen in Beijing Ditan Hospital since 2009 were enrolled.Clinical manifestations,pathological examinations,immunity levels,Epstein-Barr virus antibody examinations,complications,treatments,and outcomes were retrospectively analyzed. Results The main clinical manifestations of these patients included intermittent fever in 2 cases,neck masses and fever in 3 ases,auxiliary lymph node enlargement in 2 cases,and abdominal pain and bloating with fever in 3 cases.Up to 7 patients were pathologically diagnosed with diffuse large B cell lymphoma(DLBCL),and 3 patients were pathologically diagnosed with Burkitt’s lymphoma.Up to 8 patients had CD4 cell counts below 200/uL,and 2 patients had a level of more than 200/μL.Up to 7 patients were negative for EBV-IgM antibodies and 3 patients were not examined.Six patients underwent different chemotherapy and their prognoses were different.One patient with Burkitt’s lymphoma alternatively took CODOXM and IVAC for 3 turns after VP chemotherapy;1 patient with liver metastasis took R-CHOP 5 times,then changed therapy regimen to R-MINE and MINE. One patient with adrenal DLBCL took CHOP 6 times.Three patients with DLBCL took CHOP 1 or 2 times.Four patients gave up treatment.Various infections and side effects occurred,including bone marrow suppression,gastrointestinal bleeding,and renal (?)stunction during chemotherapy.Six patients took HAART,and 4 did not.Six patients died,whereas 3 patients got improved;and 1 (?)atient was discharged. (?)clusions AIDS patients with malignant lymphoma had various clinical manifestations,were immunocompromised,and had (?)e metastases when they were admitted;they were already in the interim or late stage of lymphoma.Chemotherapy was not (?)tive,and additional complications occurred.HAART failed to improve patient prognosis,and the overall prognosis was poor.
基金
supported by a grant from the Major Scientific Projects of the National Eleventh Five-year Special Planning in Prevention and Treatment of Main Infectious Diseases, such as AIDS and Viral Hepatitis(No.2008ZX10001-006)
